Navamedic ASA: Q1 2020 financial results
Oslo, 14 May 2020 – Navamedic ASA (OSE: NAVA) grew revenues by 22% in the first quarter of 2020 compared to the same quarter last year, driven by strong performance in Medical Nutrition and Obesity, and the return of Imdur® sales. The company reported revenues of NOK 55.6 million in the first quarter of 2020 with an EBITDA of NOK 0.7 million. Navamedic reiterates its mid- to long-term ambition of building a NOK 500 million company.“We had a solid start to the year delivering revenue growth across all key categories, displaying the attractiveness of the product portfolio and the value of our